Goudra Basavana Gouda, Singh Preet Mohinder, Chandrasekhara Vinay
Department of Anesthesia and Intensive Care, Hospital of the University of Pennsylvania, Philadelphia, PA, USA,
Dig Dis Sci. 2014 May;59(5):920-7. doi: 10.1007/s10620-013-2996-z. Epub 2014 Jan 8.
In May 2013, the FDA (Federal Drug Administration) approved SEDASYS(®), a device that enables non-anesthesia physicians to provide mild-to-moderate sedation to patients undergoing colonoscopy and esophagogastroduodenoscopy. SEDASYS(®) is the first among the devices being built to provide computer-assisted personalized sedation. Although the intention of this approval is to cut the anesthesia related expenses, it is likely to create new challenges to the users-both clinical and administrative-that might even increase the cost. Deep sedation is required frequently for a successful completion of the procedure, which poses unforeseen challenges. The present review aims to provide clear information to the users regarding pre-procedure assessment, possible sedation related complications and management options.
2013年5月，美国食品药品监督管理局（FDA）批准了SEDASYS(®)，这是一种能让非麻醉科医生为接受结肠镜检查和食管胃十二指肠镜检查的患者提供轻至中度镇静的设备。SEDASYS(®)是正在制造的用于提供计算机辅助个性化镇静的设备中的首个产品。尽管此次批准的意图是削减与麻醉相关的费用，但它可能会给临床和管理方面的使用者带来新挑战，甚至可能增加成本。为成功完成该操作，经常需要深度镇静，这带来了一些不可预见的挑战。本综述旨在为使用者提供有关操作前评估、可能的镇静相关并发症及处理方案的清晰信息。
